Delstrigo

Phase 3Small molecule

PProfessor Francois Venter

Delstrigo is one of 12 small molecule programs targeting First-line. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-LineActive, not recruiting

First-LinePhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in First-Line

#DrugCompanyPhaseTrials

COLUMVI

Roche

Phase 2

1 2

Polivy

Roche

Phase 2

1 3

Brukinsa

BBeOne Medicines

Phase 2

1 4

AAA617

Novartis

Phase 2

1 5

PM8002

BBiotheus Inc.

Phase 2

1 6

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 7

Targeted Therapy

FFudan University

Phase 2

1 8

Delstrigo

PProfessor Francois Venter

Phase 3

1 9

EGFR-TK Inhibitor

LLuBing

Phase 2

1 10

PM1009

BBiotheus Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tenofovir Disoproxil Fumarate1 trial

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

Completed·HHospital Clinic of Barcelona·Phase 4·NCT04233372·399 enrolled

Itching1 trial

The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients

Terminated·CChelsea and Westminster NHS Foundation Trust·Phase 4·NCT05289986·18 enrolled

First-line1 trial

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Active, not recruiting·PProfessor Francois Venter·Phase 3·NCT05924438·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Delstrigo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Delstrigo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Delstrigo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Professor Francois Venter company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PProfessor Francois Venter

Delstrigo

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tenofovir Disoproxil Fumarate1 trial

Itching1 trial

First-line1 trial

References

Drug Info

Quick Facts

Related News